The biotech industry is pushing lawmakers to pass a law this year that allows follow-on biologics to be sold on the U.S. market, before the 2008 elections are expected to overshadow issues that include the sector's interests. "We've made good progress in having this issue understood by the people who are in place on Capitol Hill now. ... And we'd like to get it done this year so we don't have to start all over again," BIO President Jim Greenwood said.

Related Summaries